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Sir,
We would like to comment on the paper ‘Factors influencing
p53 expression in ovarian cancer as a biomarker of clinical
outcome in multicentre studies’ by de Graeff et al (2006). In this
multicentre study, the following classification of p53-immuno-
histochemical staining results was used: moderate or strong
positivity in 450% of tumour cells was considered as aberrant,
while other staining patterns (complete lack or weak overall
staining or moderate-strong staining in o49% of tumour cells)
were classified as normal. In univariate analysis, aberrant p53 was
associated with shorter progression-free survival (PFS), but not
with overall survival. In multivariate analysis, no independent
prognostic value for p53 expression was found. The rationale
behind this interpretation of immunohistochemistry is that in-
frame point mutations of p53 alter the conformation of the protein
and prolong its biological half-life, thus intensifying the immuno-
histochemical staining result.
However, this interpretation of p53 immunohistochemical stain-
ing leads to false-negative findings (Nenutil et al, 2005). Other
mechanisms that abolish p53 activity (e.g. homozygous deletion of
the gene or truncating mutations) may result in loss of p53 protein
and are identified as absence of staining by using sensitive
immunohistochemical assay. Null mutations of p53 (nonsense,
frameshift and splice-site mutations), which in most cases are
associated with negative immunostaining, have been reported in
approximately one-fifth of ovarian carcinomas and predict poor
patient outcome (Sood et al, 1999; Shahin et al, 2000). On the basis
of this concept, we evaluated the prognostic value of three distinct
staining patterns of p53 in serous ovarian carcinoma: ‘normal’
corresponding to heterogeneous positivity that is observed in
respective normal tissue (i.e. epithelium of the fallopian tube),
‘excessive’ where the majority (450%, usually 485%) of tumour
cells show homogeneous moderate or strong positivity, and
‘completely negative’, in which no staining is found in any of the
carcinoma cells. Both excessive (in 43% of cases) and completely
negative (in 16% of cases) p53 staining conferred poor prognosis in
serous ovarian carcinoma (Lassus et al, 2003). Using this classifica-
tion, aberrant (excessive or completely negative) p53 expression was
a strong and independent prognostic factor for overall survival (OS)
in serous ovarian carcinoma. Note that the different staining
patterns were distinct, and independent evaluation by two authors
was concordant in 97% of the 522 cases (examples of different
staining patterns are provided as Supplementary data with the
electronic version of the article Lassus et al, 2003).
de Graeff et al (2006) attempted to validate the classification
system we adopted in the serous carcinoma cases of their material.
They reported no strong association of p53 with clinical outcome.
However, the justification of the conclusion is obscure as, in
multivariate analysis of OS, the P-value was statistically significant,
0.035. No confidence intervals were presented for the hazard ratios
(HR), and there was no information about the proportion of
completely p53 negative tumours. Overall, in their material, the
association of p53 with poor patient outcome seems stronger
with the new classification system (PFS, P¼0.094, HR 1.48; OS,
P¼0.035, HR 1.70) as compared to the conventional one (PFS,
P¼0.228, HR 1.16; OS, P¼0.362, HR 1.13), even though the
number of cases was much smaller for the analysis using the new
classification system as only serous carcinomas were included
(n¼225 vs n¼476). It is unclear why they chose to present the
findings based mainly on the conventional classification of p53
immunostaining.
Both in the study by de Graeff et al (2006), as well as our study
tumour grade and residual disease remained strong independent
prognostic factors. This is consistent with the literature (Friedlander,
1998), and it may be unrealistic to find molecular prognostic
markers that would overcome such strong clinical factors.
The molecular mechanisms leading to completely negative p53
immunostaining deserve further studies. In addition to truncating
mutations of the gene, other possible mechanisms include
homozygous deletion and regulation at transcriptional or transla-
tional level. In breast cancer, the p53-related expression fingerprint
has been shown as a stronger prognostic factor than mutational
status (Miller et al, 2005). However, transcriptional fingerprint
analyses are laborious and more suitable for scientific purposes.
The advantage of immunohistochemistry is that it is easily
applicable to routine clinical practice. Immunohistochemistry of
p53 downstream genes, especially MDM2, may further improve the
accuracy of immunohistochemistry in detecting non-functional
p53 (Nenutil et al, 2005). Published online 17 April 2007
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